It is the second set of jury verdicts relating to its sexed semen technology.
The court found that the group had materially breached the confidentiality obligations under the 2012 semen sorting agreement between the parties.
It follows Wednesday's verdict that Sexing Technologies had wilfully maintained a monopoly in the US sexed semen market since July 2012.
The jury will now consider a verdict on damages in relation to these matters later this week.
“We expect Genus will incur damages for the infringement of patents and breaching of confidentiality obligations but will benefit from consequences that ST was found to be maintaining a monopoly,” said analysts at Liberum.
“Most important will be implications for the existing contract between the two companies and whether Genus will be free to launch its new technology.”
The broker said investors will need to wait for these additional court decisions for clarity on the financial and strategic implications for Genus and its technology.
Genus’s sexed semen process is a novel technology for sexing bovine semen that does not subject the sperm cells to high pressures and forces.
Dairy farmers prefer female calves, and the use of gender skewed sexed semen in artificial insemination provides customers with female calves from elite genetic lines.